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INTRODUCTION 
 
1 ISCHEMIA AND THERAPEUTIC APPROCHES 
 
1.1 Ischemia and ischemic disease 
 
In medicine, ischemia (Greek , isch- is restriction, hema or haema is blood) is defined 
as an absolute or relative shortage of blood supply to an organ, where relative shortage means 
the mismatch of blood supply and blood request of a particular tissue. Occlusion of blood 
flow from the supplying artery leads to oxygen deprivation with associated injury to organs. 
Ischemia is characterized by narrowing and occlusion of arterial vessels, eventual reduction in 
distal perfusion, and by local compensating mechanisms, which include capillary growth, the 
development of collateral arterial vessels 1, 2 (arteriogenesis) and the regeneration of the 
vascular endothelial barrier due to incorporation of progenitor cells into blood vessels 
(vasculogenesisi) (Fig.1).  
 
 
Capillary growth occurs as a sprouting of small endothelial tubes from pre-existing capillary 
beds in response to local hypoxia. It is mediated by hypoxia-induced release of cytokines, 
Fig.1 Angiographic image of femoral artery occlusion. 
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chemokines and growth factors. Arteriogenesis leads to enlargement of pre-existing collateral 
arterioles in parallel orientation with the obstructed vessel. Both collateral artery and capillary 
growth are sometimes collectively called angiogenesis which reflects common therapeutic 
implications (Fig.2). Vasculogenesis occurs when circulating or bone marrow (BM)-derived 
progenitor cells respond to chemotactic and angiogenic factors and migrate and proliferate, 
where there is a request of new vessel formation. 
 
 
 
 The consequences of ischemia depend on the tissue area involved in the development of the 
occlusion, the duration of blood supply arrest, the presence of collateral circulation and the 
vulnerability of a given tissue to hypoxia 3.  
Ischemic diseases, such as cerebrovascular disease, coronary artery disease and peripheral 
artery disease (PAD), have become a significant problem in many countries because of their 
high incidence of morbidity, mortality and consequent high healthcare cost.  
PAD at stage of critical limb ischemia is a highly prevalent disease (300/500 per million in 
US) with a high unmet medical need. Critical limb ischemia is characterized by pain at rest, 
ulcers and gangrene of affected leg. In addition, critical limb ischemia patients have a 
Fig. 2 Angiogenesic mechanisms 
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significant number of comorbidities, including cardiovascular disease (angina, myocardial 
infarction) and cerobrovascular disease (stroke). The expected mortality rate in this 
population is up to 30% per year 4. Risk factors for critical limb ischemia are mainly, but not 
exclusively, smoking, atherosclerosis and diabetes 5. For all stages of the disease, 
minimisation of risk factors is mandatory. The mainstay of therapy for severe, limb-
threatening ischemia is either surgical or endovascular revascularisation aiming to improve 
blood flow to the affected extremity. If revascularisation has failed or is not possible, major 
amputation is often necessary 6. Consequently, exploring new strategies for revascularisation 
of ischemic limbs is of major importance. Stem and progenitor cells have been identified as a 
potential new therapeutic option to induce therapeutic angiogenesis. This approach aims at 
improving the vascularization of the ischemic leg so that perfusion increases sufficiently for 
wound healing to occur, and at resolving of pain at rest, thus ultimately allowing limb 
salvage. 
 
1.2 Regenerative Medicine and Cell Therapy 
 
As mentioned above, rapid revascularization of injured, ischemic and regenerating organs is 
essential to restore organ function. Cell-based therapy is a promising approach to induce 
neovessel formation. The term "cell therapy" identifies medical treatments that replace drugs 
with cells, or better, that involve the use of particular cell subpopulations, subjected to ex vivo 
manipulations, such as cell expansion/pretreatment and/or forced specific gene 
overexpression by vectors such as adenovirus, lentivirus etc.  
Cell therapy protocols generally require cell isolation from patients, in vitro manipulation and 
delivery of manipulated cells into the circulation or damaged tissue. The use of autologous 
cells permit to overcome the rejection problem (Fig.3).  
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The clinical applicability of cell transplantation is presently being evaluated in clinical trials 
but, in spite of the considerable enthusiasm in this novel potential therapy, many important 
questions are still unanswered. The major opened questions about cell therapy are: source and 
type of stem cells, delivery and engraftment of donor cell after transplantation.  
For instance, stem cells from individuals with cardiovascular risk factors, including diabetes 7-
11
, hypercholesterolemia 12, hypertension 12, 13, and/or smoking 14, 15, exhibit a limited 
therapeutic potential. For this reason, many molecular strategies have been proposed to 
augment poor engraftment and survival of transplanted cells in injured tissue.  
 
 
 
Fig.3 Scheme of stem cell therapy approach 
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To increase homing and engraftment, stem cells could be pre-treated or target tissues could be 
pre-activated. Cell pretreatment approaches deal with ex vivo stem cell pharmacological pre-
stimulation or genetic modulation.  
The pharmacological treatment with factors which orchestrate improved survival, 
proliferation, adhesion 16, migratory capacity and differentiation may significantly improve 
stem cell effectiveness in tissue repair process 17. Actually, it has been demonstrated that ex 
vivo stimulation with SDF-118, 19, VEGF 20 and bFGF 21, β2-integrins activators as HMGB1 16, 
statins 22, 23 or eNOS enhancing drugs 24, 25 improves several biological stem cell functions. 
With regard to genetic modulation, delivery of angiogenic growth factors 26 or overexpression 
of kinases have given encouraging results 27.  
More recently, it has been pointed out that also co-administration of different types of 
vascular progenitor cells may constitute a novel therapeutic strategy for improving treatment 
of ischemic disease 28. Foubert et al.28 demonstrated that coadministration of endothelial and 
smooth muscle progenitor cells may trigger the formation of more stable and functional 
vascular networks.  
As mentioned above, the pre-activation of damage target tissue represents an alternative 
choice to augment cell homing and integration. Actually, direct injection of chemotactic 
factors, as VEGF and SDF-1, may be useful to attract infused progenitor cells in injured 
tissues 29.  
In addition to molecular strategies, optimization of cell delivery could help to enhance the 
effectiveness of transplantation cell therapy. Different methods have been employed to deliver 
stem cells to the damage tissue. Nowadays repeated stem cells infusions 30 and combined 
intra-arterial and intramuscular transplantation of autologous stem cells 31 are clinically 
feasible and minimally invasive therapeutic options for patients with ischemic diseases.  
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2 PRECONDITIONING: A NEW STRATEGY TO ENHANCE STEM 
CELL THERAPY 
 
The term “preconditioning” relates to the phenomenon whereby brief episodes of a particular 
stress, i.e. hypoxia, anoxia or acidosis render tissues more resistant to subsequent ischemic 
injury. Thus, preconditioning is an endogenous protective mechanism activated by a mild 
stress that makes tissues better able to cope with another similar or greater stress.  
The important conceptual implication of the discovery of preconditioning has been the 
realization that tissues can sense and adapt to the environment: when exposed to a stress, they 
can change their phenotype in a manner that is conducive to self-preservation. This innate 
plasticity of tissues can be translated to cells.  
In this sense, the preconditioning treatment could be adopted as a new strategy to improve cell 
therapeutical potential, because cells develop a higher tolerance to the ischemic environment, 
prior injection into damaged tissue. There are many advantages in using a preconditioning 
approach for cell-based therapy. For instance, by increasing cell survival in the graft, fewer 
donor cells would need to be implanted in damaged tissue.  
A prominent enhancement in cell survival could be advantageous for cell therapies in which 
supply of transplantable cells is limited. In addition, transplanting preconditioned treated cells 
may create a more supportive environment within the host tissue by secretion of angiogenic 
factors. Further, the preconditioning treatment could enhance the recruitment and retention of 
transplanted progenitor cells, that is crucial to adequately replenish the resident progenitor cell 
pool and to maximize its regenerative potential.  
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2.1 Acidosis and acidic preconditioning 
 
Tissues are exposed to an acidotic pH in a variety of pathological conditions, including 
ischemia, diabetic ketoacidosis, wound healing, respiratory failure, and uremia and in 
response to some drugs and poisons (DuBose Harrison’s Principles of Internal Medicine. 
14th ed.). Furthermore, acidification also occurs in physiological conditions; a decrease in 
endothelial cell pH is observed in response to hydrodynamic shear stress 32, and intracellular 
acidosis is part of the physiological response to physical exercise 33. It has been demonstrated 
that acidification enhances endothelial cell Ca+2 34 and induces intercellular adhesion 
molecule-1 expression on the endothelial cell surface 35.  
Further, acidic pH inhibits endothelial cell proliferation, chemotaxis, and differentiation and 
protects endothelial cells from cellular apoptosis, in part, via the Axl molecule 36. Acidosis 
attenuates endotoxin-induced nuclear factor-kappa B (NFkB) activation in pulmonary artery 
endothelial cells and induces cyclooxygenase-2 expression 37. Moreover, acidosis affects the 
expression of target genes 38, such as vascular endothelial growth factor (VEGF) 39, matrix 
metalloproteinase (MMP)-1, and IL-8 40. Acidification also occurs in ischemia, when the 
shortage of the blood supply, due to vessel occlusion, leads to hypoxia into tissue. Indeed, 
oxygen deprivation switches the aerobic into anaerobic metabolism and induces the 
accumulation of acidic species, as hydrogenions, into the cell cytosol. Acidification that 
follows hypoxia may constitute an effector of hypoxia-mediated cell functions 41 or may exert 
biological activities by itself. The ischemic tissue produces numerous cytokines, chemokines, 
and growth factors that may influence stem cell–mediated repair 42, 43. SDF-1 is critically 
involved in the recruitment and tissue retention of progenitor cells 44-47, and the expression of 
both SDF-1 48 and its receptor, CXCR4 49, are upregulated in ischemic tissue (see page. 24). It 
is now clear that different ex vivo strategies can be adopted in order to enhance bone marrow-
derived cell regenerative properties 50 and the positive effect of some of these interventions, 
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has been related to the enhanced expression of CXCR4 51-54. Even if acidosis was found to be 
an important stress factor under ischemic conditions, according to the preconditioning 
paradigm, “almost any stress factor that is potentially harmful for cells can elicit a 
preconditioned state, i.e. increased resistance to the damaging stress, when applied in small 
quantities” 55. Therefore, probably, a short acidic pre-treatment may protect cells against 
ischemic stresses. Preconditioning with brief episodes of acidosis is known to limit 
ischemia/reperfusion injury in the heart 56-59, lung 60, 61 and endothelium 62, 63; however, the 
mechanism(s) underlying this response have not been fully elucidated. Possible mechanisms 
include activation of prosurvival kinases, such as Akt and ERK, and the overexpression of 
anti-apoptotic protein Bcl-XL. As just mentioned, the SDF-1/CXCR4 axis is a major player in 
the response to ischemia. Interestingly, acidosis regulates CXCR4 expression in a cell-specific 
manner. In fact, it induces a marked decrease of CXCR4 expression at pH 7.0 in endothelial 
cells 64; a pH-dependent CXCR4 mRNA up-regulation is insteaobserved in NT2-N neurons 
during hypoxia and reoxygenation 65, while in other cell types CXCR4 levels are unchanged 
64
.  
Since prior studies have established that progenitor cell transplantation leads to tissue 
regeneration following acute ischemia 66, these cells represent an attractive population to 
develop cell therapy enhancement strategies.  
 
3 STEM CELLS 
 
3.1 Self renewal and stem cells niche  
 
Stem cells are by definition, undifferentiated cells able to generate other stem cells of 
identical differentiation potency or produce cells that differentiate along a lineage pathway. 
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These two different activities of stem cells are described as symmetric and asymmetric 
division (Fig. 4).  
 
 
 
 
Both modes of stem cell division are necessary to maintain the cellular homeostasis within 
several tissues. In fact, although symmetric division enables the niche to be perpetuated and 
eventually amplified in time, thus allowing to renew and increase the stem cell pools and 
preventing stem cell exhaustion, asymmetric division provides the basis for the generation of 
tissue committed progenitors that are necessary for the renewal of the tissue itself and, at the 
same time, allows the maintenance of the stem cell pools in a steady state condition. 
In the symmetric division, a stem cell in the stem cell “niche” simply “self-renews” or 
differentiates. In this mode of division, the stem cell gives rise to two daughter cells of the 
same undifferentiated potency or two daughter differentiated cells. In the asymmetric 
division, each stem cells divides to generate one daughter cell with a stem-cell fate (self-
renewal) and another daughter cell that differentiates 67, 68. 
Fig. 4 Stem cells divide to self-renew as well as to produce differentiating daughter cells. Most stem cells divide 
slowly, whereas differentiating cells are derived from a lineage committed, rapidly dividing daughter cell. After 
transplantation, the stem cells divide symmetrically to produce identical, self-renewing daughter cells to replenish 
the stem cell pool (transient amplifying pool). Some of these cells then divide asymmetrically after one or more 
self-renewing, symmetric divisions to give rise to one identical stem cell and another precursor cell that divides 
rapidly and symmetrically to give rise to committed progenitors . 
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In conclusion most of stem cells have the ability to switch between asymmetric and 
symmetric division modes, and the balance between these two alternative division 
possibilities is tightly modulated by factors acting at the level of the stem cell niche. 
The regulation of stem cell self-renewal is guaranteed by stem cell interaction with their 
“niche”, defined as a specific anatomic locations that create an “ecological” 
microenvironment able to regulate stem cell self-renewal and/or their differentiation 69 (Fig. 
5).  
 
 
 
Different cell types, matrix glycoproteins, secreted growth factors and the three-dimensional 
organization provide structural and functional environments for the integrity of the stem cell 
niche and renewal and differentiation events in the stem cell pool.  
 
3.2 Types of stem cells 
 
3.2.1 Embryonic stem cells 
 
Embryonic stem cells have been classified by their developmental potential: totipotent (able 
to give rise to all embryonic and extra-embryonic cell types), pluripotent (able to give rise to 
Fig. 5 The architectural space, the physical engagement of 
the cell membrane with tethering molecules on neighbouring 
cells or surfaces, signalling interactions at the interface of 
stem cells and niche or descendent cell, paracrine and 
endocrine signals from local or distant sources, neural input 
and metabolic products of tissue activity togheter regulate 
the stem cell niche. 
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all cell types of the embryo) and multipotent (able to give rise to a subset of cell lineages). By 
this classification, the zygote is the first totipotent stem cell, able to generate the whole 
embryo, the extra-embryonic tissues and all adult organs. After several cycles of symmetric 
cell divisions, a primary differentiation occurs, that segregates the first extraembryonic 
lineage (the trophectoderm) from the embryo. At this stage, the embryo, composed of 
totipotent cells and the trophoblast is called the blastocyst. Inner cells within the blastocyst 
constitute the inner cell mass (ICM), that is the cell mass forming the embryo proper (Fig. 6). 
Pluripotent embryonic stem (ES) cells were first derived in vitro from cells obtained by the 
ICM, of mice blastocysts 70, 71. They were later isolated from human ICM 72.  
ES cells can be grown and propagated indefinitely in vitro in their undifferentiated state 
retaining a normal karyotype for long time, although it has recently been shown that long time 
in vitro culture can induce the accumulation of small genetic alteration 73. The main property 
of mouse and human ES cells is that of maintaining, in the presence of leukemia inhibitory 
factor (LIF), multilineage differentiation ability into all cell types 74. Removing LIF and 
adding grow factors to media is possible to induce differentiation towards neural, ectodermal 
or mesodermal lineage. 
 
 
 
Fig. 6 Pluripotency of embryonic stem cell  
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The ethical issue surrounding the use of human ES cells 75 is certainly the most important 
problem to resolve. This drawback has lead researchers to seek alternative undifferentiated 
cells. 
 
3.2.2 Adult stem cells 
 
It has been believed for a long time that adult mammalian stem cells are only present in 
organs that have high cell turnover rates such as blood, skin, gut, testis, and the respiratory 
tract. In fact in these organs the existence of stem cells reside in niches that support all the 
requisite factors and adhesive properties to maintain their viability and produce an appropriate 
balanced output of mature progeny over the lifetime of the organism, have been classically 
reported. 
Other organs respond poorly to regenerative pressure (e.g., the brain and the heart). This 
observation has led to the conclusion that these organs lack stem cell function and thus, upon 
injury, are not able to regenerate. More recently it has been found that even organs that were 
considered post-mitotic undergo cell turnover due to activity of stem cell pools that 
continuously generate, although at low rates, new differentiated cells that replenish lost cells  
76, 77
. These observations have led to studies aimed at identifying additional tissue-resident 
adult stem cell populations and evaluating their regenerative potential.  
In the adult soma, tissue-resident stem cells have been generally thought as tissue-specific, 
able to give rise only to progeny cells corresponding to their tissue of origin. Numerous 
evidences have, however, challenged this long-held belief. In particular, haematopoietic and 
neural stem cells appeared as the most versatile at cutting across lineage boundaries. Such 
studies suggested that unfractionated BM cells, or BM cells enriched by various methods for 
haematopoietic stem cell activity, contribute at low levels to multiple non-haematopoietic 
tissues following transfer into lethally irradiated, and often injured, recipient mice or humans 
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78, 79
. For example, it was reported that donor-derived Hematopoietic Stem Cells (HSCs) can 
be induced in vivo to trans-lineage differentiation giving rise to cells expressing skin, lung 
epithelium, liver parenchyma, skeletal muscle, endhotelium, myocardium, and neuronal 
markers 80-84. Neuronal stem cells from adult mouse brain were reported to be able to produce 
blood cells and immune cells 85, skeletal muscle cells 86, and, when injected into a blastocyst, 
a wide variety of embryonic cell types 87, thus demonstrating the apparent absence of lineage 
restriction. 
At present, there are different paradigms that may explain these results: 1) trans-
differentiation, 2) de-differentiation, 3) heterogeneity or 4) cell fusion (Fig. 7) 
 
 
 
 
 
1) Cell trans-differentiation is one mechanism by which adult stem cells may 
contribute to cell types of different lineages. In this case, lineage conversion was 
proposed to occur directly, by activation of an otherwise inactive differentiation 
program to alter the lineage specificity of the stem cell (Fig. 7A). In this mode of 
differentiation, environmental cues are supposed to play important roles in stem 
cell lineage decisions. Several evidences of this ability have been provided in 
different adult tissues especially after tissue injury. 
Fig. 5 Schematic diagram depicting potential mechanisms of adult stem cell 
plasticity see text for details. tissue-specific stem cells are represented by 
orange or green ovals, pluripotent stem cells by blue ovals, and differentiated 
cells of the “orange” lineage by red ovals and of the “green” lineage by green 
hexagons. 
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2) Dedifferentiation may theoretically occur via conversion of a lineage restricted 
stem cell into a totipotent-“like” cell  followed by reprogramming along a different 
lineage pathway (Fig. 7B). Examples of this process are provided by blastema 
formation in urodele amphibians 88 or, in mammals by the regeneration process of 
peripheral nerves in rodents that occurs by dedifferentiation of Schwann cells into 
either myelinating or non-myelinating  Schwann cell progenitors, depending on the 
type of axon to repair 88. Dedifferentiation of mammalian cells has been observed 
in cell culture. Cultured chondrocytes, for instance, can revert to fibroblast-like 
precursor cells and back again, in response to changes in extracellular matrix 89. 
Remarkably, even multinucleated, postmitotic, skeletal muscle cells can be 
induced by treatment with the purine derivative myoseverin to break up into 
mononuclear cells that reenter the cell cycle 90. Finally differentiated cells can be 
reprogrammed to an embryonic-like state by transfer of nuclear contents into 
oocytes 91 or by fusion with embryonic stem (ES) cells 92. Finally Takahashi K and 
Yamanaka S 93, demonstrated induction of pluripotent stem cells from mouse 
embryonic or adult fibroblasts by introducing four factors, Oct3/4, Sox2, c-Myc, 
and Klf4, under ES cell culture conditions. These cells, which were designated iPS 
(induced pluripotent stem) cells, exhibited the morphology and growth properties 
of ES cells, expressed ES cell marker genes, induced terathoma following their 
subcutaneous transplantation into nude mice resulted in tumors containing a 
variety of tissues from all three germ layers and when injected into blastocysts, iPS 
cells contributed to mouse embryonic development 93. 
3) The paradigm of the cellular heterogeneity within the stem cell niche states that 
tissues may contain more than a single lineage-restricted stem cell type. 
Demonstration of a third explanation for observations of adult stem cell plasticity 
relates to the purity or homogeneity of the test population. In order to demonstrate 
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definitively transdifferentiation of a particular lineage-specific stem cell, it is 
essential to exclude the possibility that multiple, distinct stem cells could be 
contributing to the observed out-come, ideally by evaluating the potential of single 
isolated stem cell. Many studies that describe stem cell plasticity are based on 
transplantation of large numbers of heterogeneous populations of cells. For 
example unfractionated BM and muscle side population cells likely contain 
multiple stem cell or progenitor cell populations, including HSC and non-
hematopoietic mesenchymal stem cells, endothelial precursors, and/or muscle 
progenitors, suggesting the possibility that distinct stem or progenitor cells could 
be contributing, consistent with their intrinsic lineage commitment and 
developmental potential, to each of the different lineage outcomes observed (Fig. 
7C). Contributions across multiple tissue types also could arise through the action 
of a single, rare pluripotent stem cell present in BM, and/or other tissues, which 
possibly copurifies in protocols designed to enrich for tissue specify specific stem 
cells (Fig. 7D). One example of this kind of stem cell can be represented by 
multipotent progenitor cell (MAPC). MAPCs were first isolated from the BM but 
they are present in multiple tissue, including brain and muscle. They are able to 
give rise to tissues of multiple germ layers in vivo and contribute substantially to 
most, if not all, tissues following injection into blastocysts 94.  
4) Cell-cell fusion  recently has been implicated in contributions of transplanted BM 
cells to liver hepatocytes, cardiac myocytes, and Purkinje neurons 77, 95, 96 (Fig. 
7E). Also ES cells can spontaneously fuse in vitro when co-cultured with neuronal 
cells or hematopoietic cells. Several authors have proposed that heterotypic cell 
fusions represent a physiological process designed to rejuvenate and/or repair a 
wide variety of tissues 77, 97. However, the low frequency with which such events 
have been observed (typically less than 1% of cardiomyocytes and 0.1% of 
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hepatocytes or Purkinje cells in nonselective transplant model) 77 implies that this 
rare phenomenon is unlikely to contribute significantly to normal tissue 
regeneration. 
 
On the basis of what described above adult stem cells represent an optimal source for cell 
therapy application.  Their use would avoid the ethical problem connected with disruption of 
the embryo during ES derivation and would also have two additional advantages (a) cells 
could be could be isolated from the patient requiring treatment, it would avoid the problem of 
immunological rejection, which would complicate the use of allogenic ES; (b) it would reduce 
the risk of tumor formation, which occurs with high frequency when ES cells are transplanted 
in vivo 71, 98. 
 
4 ENDOTHELIAL PROGENITOR CELLS (EPCs) 
 
Endothelial progenitor cell (EPC) are typical adult stem cells used in cell therapy protocols 
for the treatment of ischemic diseases (Fig. 8). EPC-based therapies can result in 
improvement of vascular perfusion and might offer clinical benefit. EPC contribute to 
neovascularization and tissue/vessel remodeling through two principal strategy: the secretion 
of cytokines and growth factors, which acts in a paracrine fashion 99; and the incorporation 
into blood vessels, which regenerates the vascular endothelial barrier 24, 100. Therefore, EPC 
administration shows a high potential in regenerative medicine.  
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4.1 Identification and characterization 
 
Formation of blood vessels occurs primarily during embryogenesis. When embryo develops, 
blood vessels are initially assembled by a process known as vasculogenesis 101, 102, which 
consists in situ differentiation of primitive angioblasts to endothelial cells. Then, a distinct 
mechanism of vascular growth is present, called angiogenesis, in which a blood vessel 
network expands through division of existing cells within the vascular network. 
In adult life, the formation of new blood vessels is not necessary unless when tissue are 
injured by ischemic conditions. In such cases, revascularization is essential. For many years, it 
was believed that angiogenesis was the sole mechanism for development of new vascular 
structures, occurring through vascular sprouting and fusion of existing vessels 102 (see page 
4). 
Ten years ago, it was suggested that formation of new blood vessels during the adult life also 
relies on the function of progenitor cells named endothelial progenitor cells (EPCs) that 
participate to the development of vascular networks by differentiating into mature endothelial 
cells 103. The bone marrow is the main source of these progenitor cells.  
Previous studies with animal bone marrow transplantation models have shown that the 
contribution of EPCs to neovessels formation may range from 5 to 25% in response to 
granulation tissue formation 104 or growth factor-induced neovascularization 105. 
Fig. 8 Representative image of EPC morphology 
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The first evidence of the existence of these cells come in 1997, when Asahara and colleagues 
isolated CD34+ haematopoietic progenitor cells from adult human peripheral blood and 
cultivated them to obtained an endothelial mature phenotype, the EPCs 100.  
In 1998, Rafii’s group reported the existence of circulating bone marrow-derived endothelial 
progenitor cells (CEPCs) in the adult. These pioneering studies clearly showed the presence 
of circulating hemangioblasts in the adult 106. 
The phenotypic characterization of EPCs remains controversial (Fig. 8), because there is a 
considerable overlap between proteins expressed on the surface of putative EPCs and those 
expressed on cells of the hematopoietic lineage. So it is currently a matter of debate which 
cell type represents the “real” EPC. In fact, EPCs were found to be positive for CD34, a 
haematopoietic stem cell marker and for VEGFR2 (named also KDR), the receptor for the 
vascular endothelial growth factor (VEGF) an endothelial stem cell marker.  
Recent studies have identified a more immature haematopoietic stem cell and EPC marker, 
CD133 (or AC133), a 5-transmembrane glycoprotein that is absent on mature endothelial cells 
and monocytic cells 107, thus CD133+VEGFR2+ cells more likely reflect immature progenitor 
cells with high proliferative potential, whereas CD34+VEGFR2+ may also represent more 
mature progenitors derived from CD133+VEGFR2+ or cells shed out of  the vessel wall. At 
present, it is unclear whether CD133 only represents a surface marker or has a functional 
activity involved in regulation of vascularization.  
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EPCs showed expression for several markers of mouse mature endothelial cells such as CD31 
and von Willebrand factor (vWF or VIII Factor) and exhibit some functional characteristic in 
culture as uptake of acetylated low -density lipoprotein (LDL) 100 or bind specific lectins 108.  
Very recent evidences suggest that EPCs may derive also by myeloid cells in the peripheral 
blood. Cells bearing the CD14 monocyte marker but expressing low amounts of CD34 form 
EPC clusters and participate to postnatal neo-vascularization in limb ischemia animal models. 
These cell population was also positive for vWF, VE-cadherin, E-selectin, VEGFR2 and 
CD45, is able to perform uptake of acetylated LDL 109. These data suggest that myeloid cells 
can differentiate or transdifferentiate to the endothelial lineage 110 and that the intermediate 
myeloid lineage may be part of the vascular repair capacity after ischemic injury. 
Interestingly, human peripheral blood monocytes acts as pluripotent stem cells and 
CD14+/CD34low express genes typical of totipotent cells 110, 111. 
Finally, several studies have shown that other non-haematopoietic cell populations can give 
rise to endothelial cells. In fact, recently it was demonstrate that in a canine chronic ischemia 
model, bone marrow-derived mesenchymal stem cells are able to differentiate in endothelial 
phenotype and into smooth muscle cells, resulting in increased vascular density and improved 
cardiac function 112. Additionally, human adipose tissue derived stem cells (ADAS) showed 
have endothelial progenitor cells characteristics. In fact, ADAS cells express endothelial 
Fig. 8 Putative cascade and expressional profiles of bone marrow-derived EPC 
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markers when cultured with Vascular endothelial growth factor (VEGF)  and in hindlimb 
ischemia model they differentiate in endothelial cells with a mechanism PI3-Kinase 
dependent, contributing to angiogenesis. 
EPCs are currently classified into two distinct types, the so-called early- and late-EPCs. Early-
EPCs, likely originate from monocytic/dendritic cells, are characterized by the expression of 
CD14 and CD45, along with endothelial markers, and have a limited proliferative potential. 
Late-EPCs display a cobblestone-like morphology, are negative for myeloid markers and 
positive for endothelial markers and have higher proliferative and clonogenic potential. 
Indeed, the EPCs concept has been recently revisited in humans according to a hierarchical 
model describing EPCs differentiation of BM-derived CD45- progenitors, characterized by the 
expression of CD133, VEGFR-2/Flk-1, and CD34 stem cell antigens. This model allowed to 
discriminate two lineage-separated cellular populations, named CFU-EC (CD45+) and ECFC 
(CD45-), that seem to play completely different roles in angiogenesis and, prospectively, in 
ischemic tissue repair 113.  
Mouse EPCs are less characterized compared with human EPCs; however, cellular 
populations present in the BM having similar activities are likely present in mice as well. In 
the mouse system, the c-kit (CD117) antigen has been used to define cells having angiogenic 
and myocardial repair potential. Indeed, it has been shown that mouse BM c-kit+ cells are 
mobilized to peripheral circulation in response to ischemia and are incorporated in the 
vasculature at neo-angiogenesis sites 46, 114. In addition, upon injection in ischemic skeletal 
muscle or myocardium, they stimulate and participate to the angiogenic process and can 
differentiate in endothelial and myocardial cells 11, 66, 84, 115, 116. Prior studies have shown that 
isolated BM c-kit+ cells seeded onto fibronectin or gelatin in the presence of fetal calf serum 
(FCS), differentiate and express numerous endothelial markers 11, 115, 116. Finally, Sata et al. 114 
showed that BM c-kit+ (Sca+/Lin2) cells yield not only endothelial cells, but also neointimal 
smooth muscle cells in a mouse model of mechanically injured femoral artery. Thus, BM c-
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kit+ cells represent a useful experimental model to study the differentiation of precursor cells 
towards the endothelial lineage and EPCs physiology.  
 
4.2 EPC mobilization 
 
A low amount of circulating stem cells is normally maintained in peripheral circulation. The 
presence of these cells is part of the normal homeostasis of the bone marrow and results from 
the equilibrium between trapping stimuli and release mechanisms. 
The formation of an ischemic microenvironment with hypoxic characteristics, as that resulting 
from an ischemic insult, represents a signal for egress of bone marrow derived-EPCS  into the 
peripheral circulation. Several studies have clarified the mechanisms governing mobilization 
of stem cells from the bone marrow. For example tissue remodeling factors like MMP-9 and 
Cathepsin-L were shown to be crucial for reallocation of stem cells from the bone marrow to 
peripheral blood. In fact, MMP-9 cleaves the membrane-bound Kit ligand (mKitL) and 
induces the release of soluble Kit ligand (Kit or stem cell factor, SCF) 117. 
The protease Cathepsin-L (CathL) was highly expressed in EPC and was essential for matrix 
degradation and invasion by EPC in vitro. CathL-deficient mice showed impair functional 
recovery following hindlimb ischemia, supporting the concept of a crucial role of CathL in 
postnatal neovascularization. This concept is strengthen by the result that infused CathL-
deficient progenitor cells neither homed to sites of ischemia nor augmented 
neovascularization 109. 
The primitive regulation of genes activated under hypoxic conditions by HIF-1α transcription 
factor establish a relationship between ischemia events and stem cells mobilization from the 
bone marrow 46.  
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In fact, two factors, i.e. the Vascular endothelial growth factor (VEGF) and the Stromal 
derived factor-1 (SDF-1), that have been implicated in angiogenesis and EPC mobilization 
are directly controlled by HIF-1α. 
Vascular endothelial growth factor (VEGF) is a 45-kDa homodimeric glycoprotein that 
stimulates proliferation and migration of endothelial cells, increasing the permeability of 
blood vessels to plasma protein 118. In the embryonic development of blood vessels and blood 
cells it plays a critical role. In fact VEGF+/- embryos are devoid of most endothelial and 
hematopoietic cells in the blood islands and die after the embryonic day (E) 9.5 for a defect in 
the formation of blood islands 119, 120. VEGF is also expressed by a subset of adult 
hematopoietic cells. In the bone marrow VEGF is secreted by hematopoietic stem cells after 
stimulation with cytokines 121 and in experiments with VEGF ablation gene, the bone marrow 
fails to repopulate lethally irradiated hosts, suggesting that VEGF controls hematopoietic stem 
cell survival during hematopoietic repopulation 122. VEGF interacts with two tyrosine kinase 
receptor, VEGFR-1 (flt-1) and VRGFR-2 (flk-1, KDR). These receptors are not only critical 
for normal embryonic development, but, especially KDR, is expressed on 0.5-1.5% of adult 
human CD34+ cells, and it has been reported in humans that a fraction of hematopoietic stem 
cells is CD34+/KDR+, so it is a marker defining hematopoietic stem cells 123. 
Stromal derived factor (SDF) 1-alpha and 1-beta belong to the chemokine family, members  
which activate leukocytes and are often induced by proinflammatory stimuli. Chemokines fall 
into two major subfamilies, distinguished structurally by the configuration of two 
characteristic cysteine residues near the amino terminus: the α-chemokine with a C-X-C 
configuration and the β-chemokine with C-C configuration. The α-chemokine include 
Interleukin-8 (IL8), melanoma growth stimulatory activity (MGSA), neutrophil-activating 
peptide-2 (NAP2) and platelet factor 4 (PF4); the β-chemokine include RANTES, 
macrophage inhibitory proteins (MIPs), 1α and 1β and monocyte chemoattractant protein-1 
(MCP-1) and stromal derived factor 1 (SDF-1). In 1988, Nishikawa et al. 124 generated mice 
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bearing a targeted mutation of the SDF-1 gene. The resulting phenotype revealed a role for 
SDF-1 in embryonic and adult hematopoiesis, CXCR4 is a known SDF-1 receptor. CXCR4 
has a seven transmembrane receptor structure and is linked to G proteins 125. CXCR4 is 
expressed on hematopoietic stem/progenitor cell, on primordial germ cells, liver oval stem 
cells, neural stem cells and skeletal muscle stem/progenitor satellite cells 126. Analogous to 
SDF-1 deficient mice, mice homozygous for CXCR4 mutation die perinatally due to defects 
in the hematopoietic and nervous systems. Signaling activated by the SDF-1/CXCR4 axis is 
critical to direct stem cell migration and their homing into the BM (Fig. 9). In 1999, Peled et 
al. 47 demonstrated that SDF-1 and CXCR4 are critical for murine bone marrow engraftment 
by human SCID repopulating stem cells. In fact, treatment of human cells with anti-CXCR4 
antibodies prevented engraftment. These authors further demonstrated that CD34+/CD38- 
cells could be converted in stem cells by pre-treatment with Interleukin-6 (IL-6) and Stem cell 
Factor (SCF) which increased the CXCR4 expression and this in turn enhanced migration 
along a SDF-1 gradient. In other studies Petit et al. 127, investigated the mobilization of 
hematopoietic stem cells induced by GCSF, a method used in clinical transplantation. After 
twenty-four hours of GCSF treatment in human and mouse bone marrow plasma and 
immature osteoblasts there was a significant reduction of SDF-1 levels and this decline was 
preceded by a sharp transient increase of marrow plasma SDF-1 protein. In contrast the 
CXCR4 expression was transiently down-regulated before being significantly up-regulated on 
stem cells after GCSF treatment, corresponding to the oscillations in SDF-1 and GCSF levels. 
The use of an antibody to either CXCR4 or to SDF-1 blocked the egress of both mature cells 
and stem cells into peripheral blood in non obese diabetic SCID mice 127.  
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The regulation of adhesion/chemotaxis of bone marrow hematopoietic progenitor cells 
involves the activation/regulation of specific integrin molecules 128. This feature is regulated 
by enhancement of substrate affinity of integrin molecules, rather than by increasing their de 
novo expression on the cell surface 47. Specifically, it was showed that SDF-1 activates LFA-1 
(Lymphocyte function associated antigen-1), VLA-4 (very late activation antigen-4) and 
VLA-5 (very late activation antigen-5) on immature human hematopoietic cells 47.  
The relevance of  the SDF-1 signaling for stem cells recruitment into PB and homing into 
hypoxic tissues, leading to vascular reconstruction has been highlighted by several papers 29, 
45, 129
. Ceradini et al.46 showed that hypoxia consequent to ischemia is an important condition 
acting on the SDF-1 tissue expression through the  action of the hypoxia inducible factor-1 
(HIF-1) 46.  
Additionally, it has been shown that HIF-1alpha regulates also CXCR4 expression 130. This 
suggests that the SDF-1/CXCR4 axis is a primary signaling pathway directing progenitor cells 
trafficking in and out of the BM and ischemic tissues.  
In fact, it has been proposed that circulating CXCR4+ stem cells having a wider differentiation 
potential compared to HSCs/EPCs may be recruited by tissue damage into several tissues 
following SDF-1 chemotactic gradients.  Thus, some of tissue-specific stem cells circulating 
Fig. 9 SDF-1/CXCR4 pathway 
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in the body may compete for occupancy of SDF-1 positive niches and this competition rather 
than stem cell plasticity, may explain apparent non canonical differentiation pathway of 
hematopoietic stem cells 83 (Fig.10). 
 
 
4.3 EPC homing 
 
The definition of stem cells homing is originated by the biology of hematopoietic stem cells 
(HSCs). Homing is fairly rapid process that traps circulating haematopoietic stem cells into 
the BM 131 and involves the activation of adhesion molecules followed by HSCs proliferation. 
A similar mechanism is supposed to act at early time points following ischemic disease when 
inflammatory cells and stem cells are recruited into the hypoxic environment. In fact, it has 
been found that progenitor cells derived from human cord blood are recruited into a tumor 
angiogenesis model, through the arrest within the tumor microvessels, extravasations into the 
interstitium, and incorporation 132.  
Fig. 10  EPC mobilization is directed by SDF-1 
gradient 
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It has been speculated that adult EPCs and haematopoietic stem/progenitor cells have the 
same behavior when recruited to the site of ischemia so they can be incorporated into newly 
formed vessels. This process is based on a multistep sequence and it includes the 
chemoattraction, the adhesion, the transmigration and, lastly, the differentiation in mature 
endothelial cells (Fig.11).  
 
 
 
Similar to BM HSC homing process, it is likely that the first step in EPC homing into 
ischemic tissues is acted through the EPCs adhesion to the endothelial cells activated by 
cytokines or growth factors expressed at early time points following ischemia, followed by 
active extravasation. The molecules allowing EPCs to adhere to endothelial cells are integrin 
molecules 133. Further, integrins and selectins are supposed to regulate rolling and adhesion of 
homing cells to the blood vessels wall, prior to their extravasation and seeding into ischemic 
tissues. Several specific integrin molecules are potentially involved in EPC homing to 
damaged tissues. For example, the very late activation antigen 4 (VLA-4) is  crucial to retain 
normal or leukemic cells in the bone marrow 134; while in NOD/SCID mice VLA-4, VLA-5 
and LFA-1 participate in the homing of CD34+ cells to the bone marrow and spleen 135. Other 
Fig. 11 Homing of BM stem cells from the blood circulation into the ischemic tissue 
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integrins seem to play a role in stem cell homing to ischemic tissues. For example, the β1 
integrin is expressed by various cell types including endothelial cells and hematopoietic cells, 
whereas β2 integrin (CD18/CD11) is found preferentially on hematopoietic cells 136, and are 
expressed on peripheral blood-derived EPCs. Moreover, the haematopoietic stem cell 
population Sca-1+/lin- lacking β2 integrins showed reduced homing and a lower capacity to 
improve neovascularization after ischemia 109. This suggests that β2 integrin mediates 
adhesion and transmigration of haematopoietic stem cells/progenitor cells during ischemia 47, 
135
. 
 
4.4 EPC differentiation  
 
On their way to the injured tissue, EPCs begin the process of differentiation into endothelial 
cells. Cytokines and mechanical forces seem to initiate a cascade of events that will lead to 
progenitor cells acquiring some phenotypic features of endothelial cells. VEGF and SDF-1 
can strongly up-regulate the expression of endothelial cell marker on progenitor cells and thus 
increase the available cell population capable of repairing the endothelial monolayer and 
improving vascular function. It has been shown that SCL/tal-1, a basic helix-loop-helix 
(bHLH) transcription factor is able to initiate the differentiation program of hematopoietic 
lineage but it is not required for endothelial cell development. SCL/tal-1-dependent process 
determines a competence to select the definitive hematopoietic lineage prior to endothelial 
differentiation 137. Although SCL is not necessarily for endothelial cells differentiation, it is 
expressed in Flk1+ cells, defined as hemangioblast. This implies that cells expressing SCL and 
Flk1 define a precursor state for endothelial and hematopoietic cells. Shear stress, the 
mechanical force generated by blood flow, can also effectively induce expression of 
endothelial-specific genes in stem cells. As recent studies revealed, laminar flow can enrich 
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both adult and embryonic stem cell populations for endothelial progenitors 138-140. 
Interestingly, histone deacetylase (HDAC) activity is essential in this process, which activates 
transcription factor p53 and p21. Commitment to endothelial lineage is sharply diminished 
when HDAC activity is inhibited, mainly because of down-regulation of HoxA9 expression. 
Forced expression of HoxA9 could rescue the endothelial differentiation imposed by HDAC 
inhibitors. In line with these findings, experiments using HoxA9−/− mice elucidated a defect in 
circulating EPCs and an impaired postnatal neovascularization capacity after the induction of 
ischemia. Interestingly, suppression of HoxA9 levels was also detected after knockdown of 
HDAC1, implying that this isoform may play a regulatory role 139. In embryonic stem cells on 
the other hand, HDAC3 was shown to be crucial in shear- and VEGF-induced differentiation 
towards endothelial cells 138. These data collectively imply that the members of HDAC family 
may serve as therapeutic targets in postnatal neovascularization.  
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AIM of THE STUDY 
 
The SDF-1/CXCR4 axis plays a pivotal role in directing stem cell trafficking from the BM 
and homing into damaged tissues. In addition, the evidence that CXCR4, together with its 
ligand, SDF-1, has a function in mobilization, homing and engraftment of progenitor cells 
suggested that its expression and/or functions may be modulated to enhance cell therapeutic 
potential in ischemic regeneration.  
The effect of acidification on cell functions has been previously analyzed in a variety of cell 
types. It has been reported that a marked and prolonged decrease in pH has a negative effect 
on cell survival and functions. In contrast, at least in endothelial cells, brief exposure to a mild 
acidotic milieu has been reported to exert a beneficial action on cell survival and, upon 
returning to a normal pH, also on cell function such as migration.  
Based on these considerations, we used an in vitro stem cell culture system that lowered 
medium pH levels from 7.4 to 7.0 in order to verify whether cell functions and CXCR4 and 
SDF-1 expression levels may be positively modulated by cell acidosis. Since prolonged 
acidosis has an inhibitory effect also on endothelial progenitor cells, it was investigated the 
potential effect of acidic preconditioning on mouse endothelial progenitor cells to increase 
their ability of adhesion, migration and differentiation in vitro and to enhance their 
regenerative potential in vivo in a mouse model of hindlimb ischemia. In addition, we 
evaluated the specific role of CXCR4 in this activity.  
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MATERIAL AND METHODS 
 
1. Animals 
  
All animal studies complied with the Guidelines of the Italian National Institutes of Health 
and with the Guide for the Care and Use of Laboratory Animals published by the US National 
Institutes of Health (NIH Publication No. 85-23, revised 1996) and were approved by the 
Institutional Animal Care and Use Committee. Swiss CD1 male mice, 4-8-week-old, were 
used for BM (BM)-derived c-kit+ cell isolation and for all in vivo experiments.   
 
2. Cell isolation and culture 
  
BM-derived c-kit+ cells were isolated by immuno-magnetic cell sorting (MINI-MACS; 
Miltenyi Biotech, Bergisch, Gladbach, Germany) and only preparations with >90% c-kit+ 
cells were used. Bone marrow cells (BM) were obtained by flushing the tibias and femurs of 
4-week-old CD1 male mice, with phosphate-buffered saline (PBS) containing 5% fetal calf 
serum (PBS-FCS). Bone marrow mononuclear cells (BM-MNCs) were then isolated by 
density gradient centrifugation with Ficoll Histopaque for 30 minutes at 2000 rpm at 18-20°C. 
After washing in PBS/5%FCS for 15 minutes at 1400 rpm, BM-MNCs were incubated with 
paramagnetic microbeads coated with antimouse c-Kit+ monoclonal antibody (Miltenyi 
Biotech) in PBS/5%FCS concentration on ice for 45 minutes. C-Kit+ cells were then separated 
on a column which is placed in the magnetic field of a MACS separator. The magnetically 
labeled cells are retained in the column while the unlabeled cells run through. The unlabeled 
cells are depleted of the labeled cells (Miltenyi Biotech). After removal of the column from 
the magnetic field, the magnetically retained cells can be eluted as positively selected cell 
fraction. The purity of c-kit+ population obtained was evaluated by FACS analysis (Fig. 12). 
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Cells were grown in Stem Span serum-free medium (Stem Cell Technologies) containing 
recombinant human cytokines. Adhesion assays were carried out in EBM-2 medium (Lonza). 
Migration assays were carried out in RPMI medium (Euroclone). Cell differentiation assays 
were carried out in M199 medium (Sigma-Aldrich) supplemented with 20% FCS or 2% FCS 
± SDF-1 (100 ng/ml; R&D Systems). In some experiments cytosolic Ca2+  [Ca2+]i  was 
enhanced adding to medium 0.5 mM of CaCl2. Cytosolic Ca2+  [Ca2+]i  was  buffered by 
loading cells with 20 M 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid-
acetoxymethyl ester (BAPTA-AM, Sigma-Aldrich) for 30 minutes prior to acidification. NO 
exposure was achieved by incubating cells for 24 hours with 500 M diethylenetriamine/nitric 
oxide adduct (DETA/NO). NO synthase inhibition was achieved by treating cells with 5 mM 
L-NAME for 24 hours prior to treatments.   
 
3. Acidification protocol 
  
Cells in 48 multiwells dishes were placed in airtight modular incubator chambers (Forma 
Scientific Inc) and infused for 20 minutes either with 5%CO2/95% air or 20%CO2/80% air to 
2. The magnetically labeled cells are 
retained in the column while the unlabeled 
cells run through. 
3. After removal of the column from the 
magnetic field, the magnetically retained 
cells can be eluted as positively selected 
cell fraction. 
1. BMMNCs were incubated with Ab anti-
cKit+ and paramagnetic microbeads 
Fig. 12 Magnetic cell sorting MINIMACS. A Method to isolate c-kit+ population 
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achieve a buffer pH of 7.4 or 7.0, respectively. Chambers were sealed and placed at 37° C in 
an incubator for the duration of the experiments.  At the end of the acidification protocol cells 
were returned to bicarbonate buffer at pH 7.4.  
 
4. Proliferation assay and analysis of cell death 
  
Proliferation assay was performed by culturing 2x105 BM-derived c-kit+ cells/ml (96 
multiwell; Becton Dickinson Labware) in 200l of growth medium. The culture medium was 
changed every two days and cells were counted daily from day 1 to day 5, indentifying viable 
cells by Trypan blue exclusion. After culture either at pH 7.4 or 7.0 for 24 and 48 hours cells 
were harvested, washed twice with PBS and cell death was determined by two different 
methods: in some experiments cells were resuspended in propidium iodide (PI) solution (PBS 
with 5µg/ml PI and 10µg/ml RNAse A; both from Sigma-Aldrich) whereas in other 
experiments cells were stained with caspase-9- or caspase-3-detection kit (Oncogene research 
products). After incubation for 30 minutes in the dark, cells were analyzed by FACS.  
 
5. Adhesion assay 
  
In these experiments, it was determined c-kit+ cell adhesion to fibronectin-coated dishes and 
to an endothelial monolayer. Cell counting was performed by an investigator blind to the 
treatment protocol. BM-derived c-kit+ cells were exposed to pH 7.0 or pH 7.4 for 24 hours in 
growth medium, then harvested and resuspended in EBM-2 medium. Fibronectin (Sigma-
Aldrich) (100 µg/mL) coating was applied to 96-well plates for 2 hours at 37°C, prior to the 
adhesion assay. Thereafter wells were blocked with 1% Bovine Serum Albumin (BSA; 
Sigma-Aldrich) in PBS for 2 hours and 105 BM-derived c-kit+ cells were added to each well 
and allowed to adhere for 3 hours at pH 7.4.  Prior to cell counting, each well was washed 
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with PBS with Ca+2/Mg+2 (Gibco) to remove debris and floating cells; adherent cells were 
fixed with 4% paraformaldehyde, stained with hematoxylin and eosin (H&E) and counted. 
For adhesion to endothelium, a monolayer of human umbilical vein endothelial cells 
(HUVECs) was prepared 48 hours before the assay by plating 2x105 cells (passage 3 to 
5)/well in 24-well plates. HUVECs were pretreated for 16 hours with TNF- (1 ng/ml, BD 
Biosciences). BM-derived c-kit+ cells were labeled with 2’,7’-Bis(carboxyethyl)-5(6)-
carboxyfluorescein tetra-acetoxymethyl ester (BCECF-AM; Molecular Probes, Eugene, OR), 
1x105 cells were added to each well and incubated for 3 hours at 37°C. Prior to cell counting 
each well was washed with PBS with Ca+2/Mg+2 to remove debris and floating cells; adherent 
fluorescence cells were fixed with 4% paraformaldehyde and counted in 10 random fields. 
 
6. mRNA extraction and qRT-PCR 
  
RNA was extracted from c-kit+ cells using Trizol reagent (Invitrogen). Approximately 106 
cells were harvested and spinned at 2000 rpm. Medium was removed and cells were washed 
twice with cold PBS. Pellets were lysed with Trizol Reagent by repetitive pipetting. The 
homogenized sample were incubated for 5 minutes at room temperature to permit the 
complete dissociation of nucleoprotein complexes. Then phase separation was performed, 
adding chloroform to sample, incubating at room temperature for about 3 minutes and 
centrifuging the sample at 13000 rpm for 15 minutes. Following centrifugation, the mixture 
separates into lower red, phenol-chloroform phase, an interphase, and a colorless upper 
aqueous phase. RNA remains exclusively in the aqueous phase. Such phase should be transfer 
carefully into fresh tube for RNA precipitation step. The precipitation of RNA was performed 
mixing the aqueous phase with isopropyl alcohol, incubating for 10 minutes at room 
temperature and centrifuging at 12000 rpm for 10 minutes. The RNA precipitate, often 
invisible before centrifugation, forms a gel-like pellet on the side and bottom of the tube.  The 
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RNA was then washed with 75% ethanol and redissolved in DEPC-treated water for 
quantification to spectrophotometer (ND-1000).  
cDNA synthesis for quantitative real time PCR (qRT-PCR) was carried out with “SuperScript 
III First-Strand Synthesis SuperMix for qRT-PCR” (Invitrogen, CA, USA). 1 g of RNA was 
mixed with RT Reaction Mix and with RT Enzyme Mix in a tube on ice. Then tubes were 
gently mix and incubated at 25ºC for 10 minutes, at 50ºC for 30 minutes and at 85ºC at 5 
minutes. The reaction was terminated on ice. cDNA obtained were used for qRT-PCR. The 
sequences of forward and reverse primers for CXCR4 gene and housekeeping gene 
(glyceraldehyde-3-phosphate dehydrogenase, GAPDH) were selected based on published 
sequence data from NCBI database. All reactions were performed in 96-well format in the 
Perkin-Elmer ABI PRISM 7000 Sequence detection system (Perkin-Elmer, MA, USA). For 
each gene of interest, qRT-PCR was performed as follows: each cDNA sample was tested in 
duplicate and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used to normalize 
transcript abundance. mRNA expression levels were calculated by Comparative Ct Method by 
using the Applied Biosystem software (Applied Biosystem, CA, USA) and were presented as 
fold induction of transcripts for target genes. Fold change above 1 denotes upregulated 
expression, and fold change below 1 denotes downregulated expression versus cells cultured 
at pH 7.4. 
 
7. Flow Cytometry 
  
C-kit+ cells were isolated by immuno-magnetic cell sorting and the purity of each preparation 
as well as the expression of CD34, Sca-1, Flk1/KDR and CXCR4 by these cells were assessed 
by FACS. Freshly isolated c-kit+ cells were incubated in PBS containing 5 % FCS for 40 
minutes on ice with fluorochrome-conjugated mAb recognizing murine c-kit (0.8-2 µg/mL; 
clone 2B8). Antibodies recognizing FITC-conjugated CXCR4 (Pharmingen), FITC-
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conjugated Sca1 (Pharmingen), FITC-conjugated CD34 (Pharmingen) and PE-conjugated 
KDR (Sigma-Aldrich) were added to 2x105 cells for 1 hour at 4° C; after incubation in the 
dark, quantitative analysis was performed by measuring 1x104 events per sample.  
 
8. Migration assay 
  
Migration was evaluated either as chemotaxis or as transendothelial migration. BM-derived c-
kit+ cells were exposed to pH 7.4 or pH 7.0 for 24 hours in growth medium; then migration of 
5x105 cells toward SDF-1 (100 ng/ml, R&D Systems) was determined in 24-well Boyden’s 
chambers at pH 7.4. For transendothelial migration, a monolayer of HUVECs was prepared 
48 hours before the assay by plating 2x104 cells (passage 3 to 5) in each well of 24-well 
Boyden’s chambers. HUVECs were kept for 16 hours either at pH 7.4 or at pH 7.0. After 
harvesting, BM-derived c-kit+ cells migrated towards SDF-1 for 5 hours at 37° C and at pH 
7.4. The number of migrating cells was counted at 40X magnification. The migration index 
(MI) was calculated by dividing the number of cells which migrated in the presence of SDF-1 
by the number of cells which migrated in response to medium alone.  
 
9. Western Blotting 
  
BM-derived ckit+ cells were lysed into Laemmli buffer (100mM Tris pH 6.8; 20% Glycerol; 
4% Sodium Dodecyl Sulphate (SDS); Bromophenol blue and 200 mM Dithiothreitol (DTT) 
and then quantified by spectrophotometer (ND-1000). 50 g of protein extract was loaded 
into a 10% SDS-PolyAcrylamide gel and electrophoresis was performed to separate denatured 
proteins. Then proteins were transferred to nitrocellulose membrane and detected using anti-
HIF-1 monoclonal antibody H1a67 (Novus Biologicals) and anti--actin antibody (Sigma-
Aldrich).  
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10. Differentiation assay 
  
BM-derived c-kit+ cells were exposed either to pH 7.4 or pH 7.0 for 24 hours in growth 
medium, then harvested and seeded at 3×105 c-kit+ cells/well in glass chamber slides (8 well 
glass slide-NUNC) coated with fibronectin (20 µg/mL, Sigma-Aldrich), in M199 medium 
supplemented with 20% FCS or 2% FCS ± SDF-1 (100 ng/ml, R&D Systems).  Cells were 
cultured for 7 days at pH 7.4 and the medium was changed every 2 days. BM-derived c-kit+ 
cell differentiation toward the endothelial lineage was determined by DiI-Ac-LDL uptake as 
well as by von Willebrand Factor (vWF) and Flk1/KDR expression. At day 6 cells were 
incubated overnight with DiI-Ac-LDL (2 g/ml, Biomedical Technologies) in serum free-
medium; then they were fixed with 4% paraformaldehyde and examined for DiI fluorescence. 
Other cells were fixed with 4% paraformaldehyde and immunofluorescence studies were 
performed with anti-vWF (vWF, DAKO) and anti-Flk-1/KDR (Santa Cruz) antibodies.  DiI-
Ac-LDL, vWF and Flk1/KDR single stained cells were counter-stained with Hoechst 33342 
(Sigma-Aldrich) nuclear dye for cell counting. In some experiments the role of CXCR4 on c-
kit+ cell differentiation into ECs was determined by adding an anti-CXCR4 antibody (20 
µg/mL, PharMingen) to the differentiation medium. A Zeiss Axioplan2 fluorescence 
microscope with image analyzer IAS (DELTA-SISTEMI version 008000) software was used 
to acquire images. Cells were counted by two readers blinded to the treatment obtaining 
similar results.  
 
11. In vivo procedures 
  
CD1 male mice, 2 month old, were anesthetized with an intraperitoneal injection (25 l/g 
body weight) of a mixture containing 1 g of tribromoethyl alcohol in 1 ml of tert-amyl alcohol 
(Avertin, Sigma-Aldrich), diluted 1:50. To produce hind limb ischemia, skin incision was 
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performed at the mid-portion of the left hindlimb overlying the femoral artery. Then the left 
femoral artery was exposed, dissected free, and excised with an electrocoagulator from its 
proximal origin as a branch of the external iliac artery till the bifurcation into saphenous and 
popliteal arteries (Fig. 13). The overlying skin was closed using surgical staples. After 
surgery, mice were kept on a heating plate at 37°C and special care was taken to monitor the 
animals until they had recovered completely from anesthesia. 
 
 
 
BM-derived c-kit+ cells were kept at pH 7.4 or pH 7.0 for 24 hours in growth medium, then 
harvested and 5x105 cells, resuspended in 50 µL PBS, were injected in the adductor muscle 
(10µl/injection) at the time of surgery in five different sites along the projection of the 
femoral artery. Laser Doppler Perfusion Imaging (LDPI; Lisca Inc) was used to record serial 
blood flow measurements over the course of 14 days postoperatively (Fig. 14). For this 
analysis the limbs were shaved. Before initiating scanning, mice were placed on a heating 
plate at 37°C to minimize variations in temperature. The LDPI uses a 12-mW helium-neon 
laser beam that sequentially scans a 12 X 12 cm surfaces area. As the scanning is performed, 
moving blood cells shift the frequency of incident light according to the Doppler principle. A 
photodiode collects the backscattered light, and the original light intensity variations are 
transformed into voltage variations in the range of 0-10 V. A perfusion output value of 0 V 
Hindlimb 
Fig. 13 Schematic view of micro-surgical intervention to induce hindlimb ischemia 
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was calibrated as 0% perfusion, whereas 10 V was calibrated as 100%. Upon termination of 
scanning, a colour-coded image representing blood flow distribution is displayed on a 
monitor. The perfusion signal is subdivided into six different intervals, each displayed as a 
separated colour. Low or no perfusion is displayed as a dark blue, whereas the highest 
perfusion interval is displayed as a red. Then Perfusion Index was defined as the ratio 
between the LDPI signal of the ischemic and contralateral paw. Previous study established 
that Laser Doppler flow velocity correlates with capillary density in the ischemic limb.   
 
Non-ischemico
Ischemico
 
 
 
12. Immunohistochemistry 
 
Perfusion is a method that allows to prepare adductor muscles to subsequent morphometric 
analysis and histological procedures, because by using paraffin it fixes and preserves the 
three-dimensional blood vessel structure. 
Normal indlimb 
Right ischemic hindlimb 
Fig. 14 Representative LDPI image after hindlimb ischemia 
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At various times after surgery, anesthetized mice were perfused with PBS, followed by 10% 
buffered formalin (10 minutes) at 100 mm/Hg, via left ventricle. After paraffin embedding, 3-
µm-thick sections were cut from each sample with muscle fibres oriented in the transverse 
direction, stained with hematoxylin and eosin, and examined. Capillary density was measured 
by counting the number of capillary profiles in 30-40 random fields/section, at 1000X 
magnification. The number of regenerating muscle fibres in the adductor muscles was 
calculated by counting the total number of fibres that showed centrally located nuclei. In other 
sections, arterioles were identified by immunohistochemistry using anti-α-smooth muscle 
actin antibody (Sigma-Aldrich) and counted.  The number of capillaries and arterioles was 
normalized to the section area calculated with IAS2000 (DELTA-SISTEMI version 008000) 
software. Counts were performed by two readers blinded to the treatment and similar results 
were obtained. 
 
13. Statistical analysis 
  
Variables were analyzed by Student’s t test and 2-way ANOVA. A value of p ≤ 0.05 was 
deemed statistically significant. Mean values are indicated ± SEM. 
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RESULTS 
 
1. Effect of acidic preconditioning on ckit+ cell proliferation and adhesion 
 
The effect of acidification on cell functions has been previously analyzed in a variety of cell 
types; it has been reported that a marked and prolonged decrease in pH has a negative effect 
on cell functions 39. At first we analysed the effect of prolonged acidification on BM-derived 
ckit+ cell functions. BM-derived ckit+ cells were isolated from 4-week old mice and exposed 
to pH 7.0. Such cells were cultured in growth medium either at pH 7.4 or 7.0 for 5 days, then 
proliferation, death and differentiation were examined. Acidification markedly inhibited the 
progressive increase in cell number observed under control conditions (Fig.15) without a 
significant effect on cell cycle (Fig. 16) and without modifying the percentage of cells 
expressing ckit, CD34, Sca-1 and KDR (Fig. 17 A,B,C,D). 
 
 
  
In additional experiments it was examined the effect of acidosis on cell death. By PI-staining 
and FACS analysis it was found that acidification enhanced cell death; in fact, while a small 
effect was observed after 24 hr at pH 7.0, a statistically significant increase was observed at 
Fig. 15 Prolonged acidosis markely inhibited the progressive increase in ckit+ cell number at pH 7.4 (N = 5) 
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the 48 hr time point (Fig. 18). Cell death under acidotic conditions was associated with an 
increase in the number of caspase-3-positive cells after 48 hr at pH 7.0 (Fig. 19). In contrast, it 
was found no significant increase in the number of caspase-9-positive cells within 48 hr 
acidification (Fig. 20).  
 
 
 
Finally, it was examined the effect of acidification on ckit+ cell differentiation toward the 
endothelial lineage. BM-derived ckit+ cells were seeded onto fibronectin-coated dishes either 
at pH 7.4 or pH 7.0 in the presence of 20% FCS for 4 or 7 days. At both time points, a marked 
decrease of DiI-Ac-LDL positive cells was found at pH 7.0 vs 7.4 (Fig. 21).   
Fig. 16 The markedly lower cell number at pH 7.0 
observed in the proliferation assay (Fig.15) was 
independent from cell cycle arrest (N = 3 at each time 
point). Cell cycle FACS analysis. 
Fig. 17 ckit, CD34, Sca-1 and KDR expression levels 
were analysed by FACS analysis.  Acidosis did not 
modulate markers’ expression (N = 4 in each 
condition) 
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Since prolonged acidosis has an inhibitory effect on BM-derived ckit+ cells and after 48 hour 
of exposure to pH 7.0 it was observed an increase in cell death, it was examined the effect of 
acidic preconditioning on cell functions. Acidic Preconditioning was achieved by exposing 
cells for 24 hours at pH 7.0 and returning them at pH 7.4 for cell analysis. Interestingly, acidic 
Fig. 18 Acidosis enhanced cell death, as assessed by FACS 
analysis of PI-stained cells (N = 9) 
Fig. 19 FACS analysis for caspase-3 shows a significant 
increase after 48 hours of acidosis treatment (N = 3) 
Fig. 20 It was found no significant effect on caspase-9-
positive cells by FACS analysis (N = 3) 
Fig. 21 After 4 and 7 days, the number of DiI-Ac-LDL+ 
cells was lower at pH 7.0 versus 7.4 (N = 3 in duplicate) 
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preconditioning did not seem to have a negative effect on cell functions, differently from 
prolonged acidosis. Indeed acidic preconditioned-cells proliferated at a rate comparable to 
control cells, that were kept at pH 7.4, throughout the 3-day course of the experiment (Fig. 
22). In additional experiments it was examined the effect of AP on BM-derived ckit+ cell 
adhesion to fibronectin and to activated endothelium, at pH 7.4.  AP enhanced BM-derived 
ckit+ cell adhesion to both fibronectin-coated dishes (Fig. 23A) and activated HUVEC 
monolayer (Fig. 23B).  
 
 
 
 
Fig. 22 Upon returning to pH 7.4, AP did not inhibit 
cell proliferation and preconditioned cells proliferated 
at a rate comparable to that of control cells (N = 3 at 
each time point) 
Fig. 23 AP enhances ckit+ cell adhesion. 
(A) Adhesion assay was performed onto 
fibronectin-coated dishes. (N = 3. (B) 
Adhesion assay of ckit+ cells onto endothelial 
cells (N = 5). Average adherent cell number  
is shown in the upper panel and 
representative images of adherent cells are 
shown in the lower panels (calibration bar = 
30 µm).  
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2. Effect of acidic preconditioning on ckit+ cell therapeutic potential in a mouse model of  
hindlimb ischemia 
 
We then evaluated the regenerative potential of AP-treated ckit+ cells in vivo, in a mouse 
model of hindlimb ischemia. Bone marrow-derived ckit+ cells were cultured in growth 
medium either at pH 7.4 or 7.0 for 24 hours, then half a million were injected into the mouse 
adductor muscle at the time of femoral artery dissection; additional control mice were injected 
with saline. Hindlimb perfusion was evaluated by LISCA for 3 weeks after treatment. The 
marked reduction in blood flow induced by acute hindlimb ischemia exhibited a slow 
recovery which was accelerated by the injection of acidic preconditioned ckit+ cells; in 
contrast, non-preconditioned ckit+ cells had no significant effect and recovery was 
comparable to that observed with saline treatment (Fig. 24A). Further, in adductor muscles 
injected with cells or saline it was evaluated angiogenesis and muscle regeneration. Capillary 
number in the adductor muscle was determined before ischemia and at different times after 
treatment. Acidic preconditioned cells increased capillary number by comparison with 
treatment with non-preconditioned cells or saline, both at the 7 and 14 day time points (Fig. 
24B). In addition, staining arterioles with α-smooth muscle actin antibody, it was found that 
treatment with acidic preconditioned ckit+ cells markedly increased arteriole number which, at 
the 14 day time point, was approximately 3-fold higher than following treatment with non-
preconditioned cells or saline (Fig. 24C). Regenerating muscle fibres differ from mature 
fibres because of the smaller diameter and central nucleus. Muscle regeneration was analysed 
7 days after hindlimb ischemia and treatment with preconditioned cells increased regenerating 
fibres over 2-fold vs non-preconditioned cells and saline treatments (Fig. 24D).  
In conclusion, acidic preconditioning seems to improve the regenerative potential of BM-
derived ckit+ cells in a mouse model of hinlimb ischemia.  
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3. Effect of acidic preconditioning on CXCR4 and SDF-1 expression 
 
Since CXCR4 signalling plays a pivotal role in precursor cell migration and homing to 
tissues, we examined whether AP modulates CXCR4 and SDF-1 expression. It was found 
that, following AP, both CXCR4 and SDF-1 mRNA levels increased by 2.5±0.4 and 1.7±0.2 
fold, respectively (Fig. 25). The percentage of CXCR4 positive cells was determined by 
FACS analysis and it was found that, at the 24 hour time points, there was a trend for 
Fig. 24 AP enhances ckit+ cell therapeutic potential in a mouse model of hindlimb ischemia.  (A) Hindlimb blood 
flow evaluated by LDPI (N = 8). (B) AP cells increased capillary number vs control cells or saline, at the 7 and 14 
day time points (calibration bar = 20 µm). (C) AP cells increased arteriole number stained  with α-smooth muscle 
actin antibody at the 14 day time point (calibration bar = 30 µm). (D) AP cells increased regenerating fibres at the 7 
day time point (calibration bar = 50 µm). Left panel shows average results (N = 6). Right panels show 
representative images.  
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enhanced protein expression in response to acidification; 52.62 % in control cells and 60.56 % 
AP cells expressed CXCR4 with a mean fluorescence intensity (MFI) of 19.64 and 24.33 for 
control and AP cells, respectively (Fig. 26).  
 
 
In additional experiments it was examined the mechanisms that may be responsible for AP-
mediated increase in CXCR4 expression. It has been previously reported that acidification 
Fig. 25 AP enhanced CXCR4 (upper panel; N = 6) and SDF-1 
(lower panel; N = 10) mRNA levels, as assessed by qRT-PCR.  
Fig. 26 The number of CXCR4+ cells and the mean fluorescence 
intensity (MFI) for CXCR4 expression were determined by 
FACS analysis at different times. Upper panel shows that at the 
24 hour time point there was a trend for enhanced protein 
expression in response to acidification. Similarly, lower panel 
shows  mean fluorescence intensity (MFI) for CXCR4 of control 
and AP cells. Both trends achieved statistical significance at the 
48 hr time point (N = 5). 
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increases [Ca2+]i and this is a key event in triggering NO production 141; further, both an 
increase in [Ca2+]i and NO have been shown to increase CXCR4 expression 51, 52. 
Interestingly, we found that [Ca2+]i buffering with BAPTA abolished not only the increase 
achieved by raising bathing [Ca2+] from 0.2 to 0.5 mM at pH 7.4, but also the AP-mediated 
CXCR4 increase. We next showed that, NO production played an important role in the 
upregulation of CXCR4 by acidosis. In fact, while BM-derived ckit+ cells, kept at pH 7.0 for 
6 hrs, exhibited an increase of DAF positivity (Fig. 27 upper panel) and the NO donor 
DETA/NO-induced CXCR4 expression upregulation in BM-derived ckit+ cells kept at normal 
pH, the NOS inhibitor L-NAME decreased DAF positivity and abolished AP-mediated 
CXCR4 increase (Fig. 27 lower panel). AP of bone marrow ckit+ cells thus enhances CXCR4 
expression, via a nitric oxide-dependent mechanism.  
 
 
Fig. 27 Representative FACS analysis of DAF 
positivity (upper panel) shows that, after 6 hours of 
acidosis, ckit+ cells exhibited an increase in NO 
production, which was prevented by L-NAME. AP-
mediated increase in CXCR4 mRNA was abolished  by 
BAPTA-AM and L-NAME (lower panel) (N = 3).  
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As HIF-1 is a regulator of CXCR4 130 and its expression is regulated by acidification 64 and 
NO 142, we investigated whether the modulation of CXCR4 expression by AP was paralleled 
by HIF-1 induction. To this end we analysed HIF-1 expression in control cells following 
exposure to DETA/NO and in AP cells treated with L-NAME. Both NO and acidification 
induced HIF-1 protein expression and L-NAME abolished this effect in AP cells (Fig. 28). 
 
 
4. L-NAME abolishes acidic preconditioning ability to enhance ckit+ cell therapeutic 
potential in vivo 
 
In light of the key role that NO appears to play in CXCR4 expression in response to AP, it 
was examined the therapeutic potential of ckit+ cells exposed to AP and treated with the nitric 
oxide inhibitor synthase, L-NAME. BM-derived ckit+ cells were treated with L-NAME, 
exposed to AP and then half a million injected into the mouse adductor muscle, at time of 
femoral artery dissection. Hindlimb blood flow perfusion analysis showed that treatment of 
BM-derived ckit+ cells with L-NAME did not accelerate blood flow recovery after acute 
ischemia. In addition, L-NAME treatment prevents the capillary number and arterioles 
increase observed in mice treated only with AP cells. At last, L-NAME attenuates also AP 
effect on muscle regeneration (Fig. 29).  
 
Fig. 28 HIF-1 expression was assessed by Western blotting analysis. In control 
cells DETA/NO increase HIF-1 and this effect was prevented by pretreatment 
with L-NAME. AP enhanced HIF-1 levels and L-NAME abolished this effect. 
This experiment was performed 3 times with similar results. 
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5. Effect of acidic preconditioning on SDF-1-driven ckit+ cell migration and 
differentiation toward the endothelial lineage 
 
In the following in vitro experiments it was evaluated the functional significance of CXCR4 
up-regulation induced by AP. BM-derived ckit+ cells were kept for 24 hours either at pH 7.4 
or pH 7.0 and then analysed for their ability to migrate in response to SDF-1. Cell migration 
Fig. 29. L-NAME abolishes AP ability to enhance ckit+ cell 
therapeutic potential in vivo. (A) AP cells exposed to L-NAME 
failed to enhance limb perfusion (N = 8). (B) L-NAME 
prevented the increase in capillary number at 7 and 14 days (N 
= 6). (C) L-NAME attenuated the increase in arteriole number 
at 14 days (N = 7). (D) L-NAME abolished the effect on 
muscle regeneration at 7 days (N = 7).  
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was evaluated, both in chemotaxis and in transendothelial migration assays, at pH 7.4. AP 
cells exhibited a higher ability than control cells to migrate in response to SDF-1 (100 ng/ml) 
and this effect was abolished upon treatment with an anti-CXCR4 antibody (Fig. 30A). SDF-
1-directed transendothelial migration assays were performed under two different conditions: 
the endothelial monolayer was constituted by HUVEC that were grown for 16 hours, prior to 
the assay, either at pH 7.4 or at pH 7.0 (Fig. 30B, upper and lower panel, respectively). Under 
both experimental conditions AP enhanced transendothelial migration.  
 
 
 
 
Fig. 30 (A) AP enhanced chemotaxis and this response was 
abolished by a selective CXCR4 blocking antibody (N = 3). 
(B) AP enhanced ckit+ cell transendothelial migration, both 
through HUVEC grown at pH 7.4 (N = 5 in duplicate; upper 
panel) and through HUVEC grown at pH 7.0 (N = 3 in 
duplicate; lower panel).  
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In additional experiments it was examined whether AP may modulate BM-derived ckit+ cell 
differentiation toward the endothelial lineage. Therefore, BM-derived ckit+ cells were 
Fig. 31 AP enhances ckit+ cell differentiation toward the endothelial lineage. In 20% FCS, AP enhanced: (A) 
DiI-Ac-LDL+ cell number (N = 10), (B) Factor VIII+ cell number (N = 4) and (C) KDR+ cell number (N = 4). 
For all markers used, average positive cell number is shown in the upper panel and representative images in 
the lower panel; calibration bar = 50 µm. (D) In 2% FCS, DiI-Ac-LDL+ cell number was similar for cells 
treated with AP versus control. SDF-1 addition markedly enhanced DiI-Ac-LDL+ cell number only for cells 
treated with AP whereas it had no effect on C cells; DiI-Ac-LDL uptake by AP cells was abolished by a 
selective CXCR4 blocking antibody (N = 6 in duplicate).  
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cultured for 24 hours either at pH 7.4 or at pH 7.0 and then seeded onto fibronectin-coated 
dishes in the presence of 20% FCS for 7 days at pH 7.4.  As shown in Fig. 23 AP increased 
BM-derived ckit+ cell adhesion; over 95% adherent cells subjected to AP expressed 
endothelial cell markers, i.e. Factor VIII, KDR and displayed Ac-DiI-LDL uptake (Fig. 31A, 
B and C).  
Further, it was examined the role of SDF-1 in AP cell differentiation. To address this point, 
culture medium was supplemented with 100 ng/ml SDF-1 and FCS concentration was 
lowered from 20% to 2 %. SDF-1 markedly enhanced the number of DiI-Ac-LDL-positive 
cells following AP whereas it had no effect on cells cultured at pH 7.4; this effect of SDF-1 
on DiI-Ac-LDL uptake was abolished by an anti-CXCR4 blocking antibody (Fig. 31D). 
Acidic preconditioning of bone marrow ckit+ cells enhances migration to SDF-1 and 
differentiation into endothelial lineage through a mechanism that involved the CXCR4/SDF-1 
axis.   
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DISCUSSION  
 
The present study shows that preconditioning with a 24 hr hypercarbic acidification pulse 
increased CXCR4 expression in BM c-kit+ cells. This effect was associated with enhanced 
SDF-1-directed cell adhesion and migration in vitro and with a potentiated angiogenic and 
regenerative action in a mouse model of hindlimb ischemia. Both in vitro and in vivo effects 
of AP were mediated by an increase in NO production.   
 
1. Acidosis versus Acidic Preconditioning  
 
The effect of acidification on cell functions has been previously analyzed in a variety of cell 
types. For instance, it has been reported that a marked and prolonged decrease in pH has a 
negative effect on cell proliferation and function, and that cell survival decreases 39, 143. In 
contrast, at least in endothelial cells, brief exposure to a mild acidotic milieu has been reported 
to exert a beneficial action on cell survival and, upon returning to a normal pH, also on cell 
function such as migration 143. These beneficial responses have been attributed to an increased 
secretion of pro-survival angiogenic factors, such as fibroblast growth factor 2 (FGF-2) and 
vascular endothelial growth factor (VEGF) and to the enhanced expression and activation of 
the tyrosine kinase receptor AXL. Upon binding to its ligand (the survival factor growth 
arrest-specific gene 6 product (Gas6)), AXL has an antiapoptotic action 36, 39. These in vitro 
studies are in agreement with in vivo results showing that preconditioning with brief episodes 
of acidosis limits ischemia/reperfusion injury in the heart 58, 59, lung 60, 61, and endothelium 63.  
Our present study examined the effect of preconditioning ex vivo with a 24 hours exposure to 
mild hypercarbic acidification on BM ckit+ cells, prior to transplantation into the ischemic 
mouse hindlimb.  
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2. SDF-1/CXCR4 axis and EPCs 
 
The study focused on the SDF-1/CXCR4 axis because SDF-1 is known to increase in 
ischemic tissues 45, 46, 51, in light of the substantial evidence supporting the key role that SDF-
1/CXCR4 axis plays in the response to cell therapy. In humans, impairment of CXCR4 
signaling reduces the proangiogenic action of endothelial progenitor cells 144 and the response 
to autologous BM cell transplantation into the ischemic heart 145. Another study has compared 
the functional activity of both CXCR4+ and CXCR4- human BM mononuclear cells and found 
that only CXCR4+ cells improved neovascularisation in a murine model of hindlimb 
ischemia; on the other hand, CXCR4- cells had no effect on tissue perfusion and on capillary 
number 145. Further, in a rodent model of myocardial infarction, hypoxic preconditioning 
augmented cardiac progenitor cell therapy efficacy by inducing CXCR4 expression 53. It is 
noteworthy that ckit+ cells exposed to AP exhibited a marked increase in SDF-1 expression, 
which is expected to have a positive action via autocrine and paracrine mechanisms. Indeed, 
SDF-1 priming of cells prior to transplantation enhances their therapeutic potential 19. Direct 
SDF-1 injection into the ischemic limb 29 and heart induces a regenerative response and 
improves function 146. Thus, the effect of an increased SDF-1 secretion by AP cells will act in 
conjunction with the increase in CXCR4 expression, which is expected to modulate cell 
distribution within the ischemic tissue in response to the SDF-1 gradient induced by ischemia 
and to also facilitate CXCR4+ cell differentiation toward the endothelial lineage.  
 
3. Proposed mechanism for the increase of CXCR4 expression 
  
The mechanisms leading to an increase in CXCR4 expression upon exposure to hypercarbic 
acidification as described here have been linked to an increase in NO production. Indeed, the 
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NO donor DETA/NO mimicked AP’s ability to increase CXCR4 expression and the effect of 
acidification, both on CXCR4 expression, and ckit+ cells regenerative potential in vivo, was 
abolished by the NOS inhibitor L-NAME.  It has been previously shown that a mild decrease 
in pH enhances NO production in vivo 147; a similar response has been reported also in vitro 
and has been associated with enhanced iNOS transcription 148. Further, we have previously 
shown that acidification increases [Ca2+]i 34, which is a key event in triggering NO production 
141, 149
. Accordingly, the intracellular Ca2+ chelator BAPTA-AM prevented the increase in 
CXCR4 expression induced by acidic preconditioning. Further, CXCR4 expression is HIF-
1α- dependent 130, 150 and, under our experimental conditions,  HIF-1α increased both in 
response to DETA-NO 142, 151, 152, and to acidification and the increase in response to AP was 
abolished by L-NAME (Suppl. Fig. 6).  Therefore, both the increase in [Ca2+]i  and in NO 
production play a pivotal role in AP-mediated increase in CXCR4 expression. It is noteworthy 
that not all cells respond to acidification with an increase in CXCR4 expression and, 
depending on the cell type, a decrease 64, 65 and an increase (present study) on CXCR4 
expression have been reported.   
 
 
 
 
 
Fig. 32 The mechanisms leading to the CXCR4 increase expression upon exposure 
to acidic preconditioning have been linked to an increase in NO production, that 
may induce the translocation of HIF-1 in the nucleus. HIF-1  recognize the 
CXCR4 promoter and induce its transcription. 
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4. Conclusion 
 
Interestingly, here we found that control ckit+ cells, without prior exposure to AP, failed to 
induce neovascularisation in vivo. This result is in apparent contrast with other studies which 
have shown a beneficial action of cell therapy with non-preconditioned BM cells in a similar 
animal model 45, 66. However, no prior study has utilized the BM ckit+ cells that were used in 
the present study.  The mechanism(s) for these different responses are beyond the scope of the 
present work, but should be an important topic that will need to be addressed in future 
experiments. In conclusion, acidic preconditioning provides a new strategy to enhance the 
therapeutic potential of BM ckit+ cell transplantation in ischemic tissues. Follow-up studies to 
examine other aspects of this novel strategy should be performed to help make regenerative 
cell therapy a reality. 
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